Morgan Stanley Lyell Immunopharma, Inc. Call Options Transaction History
Morgan Stanley
- $1.36 Trillion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LYEL
# of Institutions
21Shares Held
55.2MCall Options Held
0Put Options Held
0-
Apoletto LTD Washington, DC15.1MShares$160 Million42.56% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$143 Million0.0% of portfolio
-
Wu Xi App Tec Co., Ltd. Shanghai, F47.39MShares$78.1 Million53.56% of portfolio
-
Mwg Management Ltd. Washington, DC1.01MShares$10.7 Million17.17% of portfolio
-
Orland Properties LTD Washington, DC755KShares$7.98 Million2.83% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $2.62B
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...